Guido Magni
Director/Board Member presso Anabasis SRL
Profilo
Guido Magni is currently a Director at Biotie Therapies AG, Anabasis SRL, Nouscom AG, Nouscom Srl, and a Member-Supervisory Board at AM-Pharma Holding BV.
He started his current position at Versant Ventures (Switzerland) GmbH in 2008.
Previously, he served as an Independent Director at Adolor Corp.
and Biotie Therapies Oy.
From 2016 to 2020, he was a Director at Aprea Therapeutics AB.
He also held positions as a Managing Director at Versant EuroVentures, a Director at Tarveda Therapeutics, Inc., Gensight Biologics SA, PIQUR Therapeutics AG, and Mosaic Biomedicals SL.
From 2018 to 2023, he is a Non-Executive Director at LAVA Therapeutics NV.
From 2016 to 2020, he was an Independent Director at Aprea Therapeutics, Inc. He has also worked at Roche Holding AG as the Head of Medical Science & Global Drug Development and at Synosia Therapeutics AG as a Member of the Management Board.
From 1993 to 2008, he was the Global Head of the Medical Science Division at Hoffmann-La Roche, Inc. He was also a Managing Partner at Aravis AG from 2011 to 2013.
Additionally, he served as a Member of the Supervisory Board at AM-Pharma BV.
Dr. Magni holds a doctorate degree from The American University of Rome (1981) and the University of Padua (1977).
Posizioni attive di Guido Magni
| Società | Posizione | Inizio |
|---|---|---|
Anabasis SRL
 Anabasis SRL Miscellaneous Commercial ServicesCommercial Services Part of Dompé SpA, Anabasis SRL provides biopharmaceutical research and development services. The private company is based in Milan, Italy. The Italian company was founded by Francesco Sinigaglia. Anabasis was acquired by Dompé SpA on February 27, 2012. | Director/Board Member | - |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Director/Board Member | - |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Director/Board Member | 11/12/2020 |
| Versant Ventures (Switzerland) GmbH | Private Equity Investor | 01/01/2008 |
Biotie Therapies AG
 Biotie Therapies AG Pharmaceuticals: MajorHealth Technology Part of Acorda Therapeutics, Inc., Biotie Therapies AG is a holding Swiss company focused on developing drugs for the treatment of psychiatry and neurology diseases. The private company is based in Zurich, Switzerland. | Director/Board Member | - |
| Nouscom Srl | Director/Board Member | - |
Precedenti posizioni note di Guido Magni
| Società | Posizione | Fine |
|---|---|---|
| LAVA THERAPEUTICS N.V. | Director/Board Member | 01/01/2023 |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Director/Board Member | 30/06/2020 |
| APREA THERAPEUTICS, INC. | Director/Board Member | 30/06/2020 |
| ░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formazione di Guido Magni
| The American University of Rome | Doctorate Degree |
| University of Padua | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| LAVA THERAPEUTICS N.V. | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 17 |
|---|---|
Adolor Corp.
 Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Health Technology |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Biotie Therapies AG
Biotie Therapies AG Pharmaceuticals: MajorHealth Technology Part of Acorda Therapeutics, Inc., Biotie Therapies AG is a holding Swiss company focused on developing drugs for the treatment of psychiatry and neurology diseases. The private company is based in Zurich, Switzerland. | Health Technology |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Health Technology |
Aravis AG
 Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Finance |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
| Versant EuroVentures | |
Tarveda Therapeutics, Inc.
 Tarveda Therapeutics, Inc. BiotechnologyHealth Technology Tarveda Therapeutics, Inc. discovers and develops cancer therapeutics and drugs. Its proprietary technology, assets and expertise are built around an integrative research and development process that brings together new-molecule drug discovery engine and patented nanoparticle engineering platform. The company was founded by Omid C. Farokhzad, Stephen J. Lippard and Robert S. Langer Jr., in 2011 and is headquartered in Watertown, MA. | Health Technology |
Anabasis SRL
Anabasis SRL Miscellaneous Commercial ServicesCommercial Services Part of Dompé SpA, Anabasis SRL provides biopharmaceutical research and development services. The private company is based in Milan, Italy. The Italian company was founded by Francesco Sinigaglia. Anabasis was acquired by Dompé SpA on February 27, 2012. | Commercial Services |
PIQUR Therapeutics AG
 PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Health Technology |
Mosaic Biomedicals SL
 Mosaic Biomedicals SL Hospital/Nursing ManagementHealth Services Mosaic Biomedicals SL develops personalized cancer treatments. It is engaged in the realization and development of scientific and technical research projects in the field of oncological and tumor diseases. The company was founded by Joan Seoane, Judit Anido Folgueira and José Baselga on April 19, 2013 and is headquartered in Barcelona, Spain. | Health Services |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Health Technology |
| Versant Ventures (Switzerland) GmbH | Finance |
| Nouscom Srl | Commercial Services |
- Borsa valori
- Insiders
- Guido Magni
